Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India likely to allow smaller gap between AstraZeneca COVID vaccine doses sold privately - sources

09/22/2021 | 01:57am EDT

NEW DELHI, Sept 22 (Reuters) - India is likely to allow a smaller gap between AstraZeneca COVID-19 vaccine doses for inoculations being carried out privately, in line with a court order, two sources told Reuters.

Private hospitals and clinics will give their paying patients the option to receive their second dose of the vaccine four weeks after the first, down from between 12 and 16 weeks currently, they said.

Earlier this month, the high court in the southern state of Kerala ordered changes https://www.reuters.com/business/healthcare-pharmaceuticals/indian-court-backs-shorter-dose-gap-those-paying-astrazeneca-vaccine-2021-09-07 in the health ministry's vaccine-booking platform to give people paying for vaccination this choice, which is already being offered to those flying abroad.

"Since the high court has given a judgement, it will have to be done," said one of the sources. "For the government's programme, the ideal gap remains 12 weeks."

India doubled the gap between the AstraZeneca vaccine's two doses in May to make sure more people were inoculated with at least one dose when supplies were scarce at the height of the country's outbreak this year.

AstraZeneca recommends the second dose of its COVID-19 vaccine be taken four weeks after the first shot, but says on its website there is a "trend of increased efficacy with a longer than 4 week dosing interval". The World Health Organization recommends an interval of eight to 12 weeks.

The sources, who declined to be named because they were not authorised to speak to the media, could not say when the changes will be implemented.

The health ministry did not immediately respond to a request for comment.

India's total vaccine output has trebled since May to 300 million doses a month. Less than a quarter of the production is sold by private hospitals while the rest is provided by the government free of cost.

India has administered at least one dose of the COVID-19 vaccine in 65% of its 944 million adults and two doses in 22% of adults. (Reporting by Neha Arora and Krishna N. Das; Editing by Ana Nicolaci da Costa)

© Reuters 2021
All news about ASTRAZENECA PLC
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
10/22European ADRs Move Higher in Friday Trading
10/22ASTRAZENECA : COVID-19 Jab Safe for Pregnant Women, No Impact on Fertility
10/21VC DAILY : ShouTi Lands $100 Million to Develop -2-
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
10/21ASTRAZENECA : JP Morgan reaffirms its Buy rating
10/20ASTRAZENECA : Credit Suisse remains its Buy rating
10/20ASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
10/20ASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
10/20KAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 441 M - -
Net income 2021 4 862 M - -
Net Debt 2021 24 847 M - -
P/E ratio 2021 35,8x
Yield 2021 2,28%
Capitalization 192 B 192 B -
EV / Sales 2021 6,11x
EV / Sales 2022 4,94x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 123,70 $
Average target price 137,81 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.83%191 835
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985